Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyFFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated PatientsPart 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.Chemotherapy-induced toxicity is highly heritable in Drosophila melanogasterGenotypes Affecting the Pharmacokinetics of Anticancer Drugs.Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.Epigenetic cancer therapy: rationales, targets and drugs.Pharmacogenetics of chemotherapy efficacy in breast cancer.Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia.Genetic polymorphisms of XPD and CDA and lung cancer riskGene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
P2860
Q26752368-5B789C8C-8C6F-4374-9B7D-71B75E6647D8Q28484288-A6641C14-86C3-4702-B212-FF6B55321FDAQ28547481-87D175ED-5D11-48A9-B112-5BA5E5C0748DQ35584977-9418BD85-1E01-4A54-9DD2-B999D5EB3D36Q35830711-D66AEF29-90C0-480D-985B-385AF21C2295Q37685527-B745F8C7-8DD4-4230-B33E-43A93B170E74Q37876401-B87DBE3B-BCC0-4812-A117-AA90432A9E87Q37969665-910B0C76-C6BD-4584-B005-1C96965BEE99Q38003703-9A429605-5EDC-4C2A-BFA0-0BE54491BBCFQ38030053-519342F1-CFB9-473D-9D89-74CF5B9A2988Q38286242-83E2ECD5-703A-4429-9ADC-CB2226C24F04Q39401851-82A4FA10-9798-4C9B-9B56-749676437F03Q41831329-6D71F08D-F592-4057-855D-81B35E33B5B1Q42734042-44C06D27-146B-424B-B474-0CA74F77C35E
P2860
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@ast
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@en
type
label
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@ast
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@en
prefLabel
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@ast
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@en
P2093
P2860
P1476
Pharmacokinetics of gemcitabin ...... ytidine deaminase polymorphism
@en
P2093
Donald R A Uges
Floris M Wachters
H Marike Boezen
Harry J M Groen
J Marina Maurer
Jan Gerard Maring
Monique Slijfer
P2860
P2888
P304
P356
10.1007/S00228-010-0799-0
P577
2010-03-06T00:00:00Z
P5875
P6179
1053088243